Sedation With Dexmedetomidine Versus Remifentanil in Urogynecological Surgery Under Spinal Anaesthesia
Unknown statusPhase 3NCT03883347
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
Neuraxial blocks are usually used as an anaesthetic method for urogynecological surgeries. In most patients under regional anaesthesia, premedication is given for reducing anxiety. Purpose of this prospective double blind randomised clinical trial is the investigation of the effect of perioperative intravenous infusion of dexmedetomidine vs remifentanil for sedation in patients under spinal anaesthesia for urogynecological procedures.
Study details
- Official title
- Sedation With Dexmedetomidine Versus Remifentanil in Urogynecological Surgery Under Spinal Anaesthesia : Impact on Block Characteristics, on Acute and Chronic Postoperative Pain
- Conditions
- Vaginal Hysterectomy
- Suburethral Slings
- Interventions
- Sponsor
- University of Athens
- Start date
- 2019-03-20
- Primary completion
- 2022-03-20
- Sex
- Female
- Age range
- from 40 Years to 75 Years
- Results posted
- No results posted in this snapshot
- Countries
- Greece
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Physical status according to American Society of Anesthesiologists (ASA) I-II * Patients scheduled for transvaginal urogynecological or gynecological surgery Exclusion Criteria: * Patient refusal * Contraindication of spinal anaesthesia (Coagulopathy, Local infection at the site of injection, Local anaesthetic allergy, Hypovolaemia) * BMI \> 30 kg/m2 * Personal history of cardiovascular disease * Arrythmias * Conduction disorders * Severe kidney or liver dysfunction * Insulin-dependent diabetes mellitus * Central nervous system disorders * Psychiatric and mental status disorders * Chronic Excessive Alcohol Consumption * Chronic Use of Opioid Analgesics * Chronic Use of corticosteroids * Chronic Use of clonidine (or other a2 adrenergic agonist) * Use of drugs acting on central nervous system or analgetics the last two weeks * Communication problems due to language barriers or unable to understand the pain scale
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT03883347